Deep search
Rewards
Search
Copilot
Images
Videos
Maps
News
Shopping
More
Flights
Travel
Hotels
Real Estate
My Bing
Notebook
Top stories
Sports
U.S.
Local
World
Science
Technology
Entertainment
Business
More
Politics
Trending on Bing
Willing to run for president
Innocent after 43-yrs of jail
'I learned nothing'
Breaks attendance record
WWII plane crash: 2 killed
Murder suspect arrested
Poll: Black voters' support
2nd American goes missing
Honeybees detect cancer?
US killed top ISIS leader?
Returns key to NYC
Calif. County wildfire
Immigrant deportation upheld
Juneteenth event shooting
France pre-election protest
‘Confident' of UFC return
Musician Tepper dies at 60
Sets record at Olympic trials
2024 US Open
Campaign rakes in $28M
‘Politics in everything’
Alwyn breaks silence on split
Oilers rout Panthers
Heading to 4th Olympics
'Lucky to be here'
Royals beat Dodgers 7-2
Earns $13M in previews
Cause of death revealed
Honduras plans 'megaprison'
Heat wave on Father’s Day
MI splash pad shooting
Voyager 1 is back online
IDF to begin 'tactical pause'
Linked to salmonella outbreak
8 ISR troops killed in Rafah
Victim of 1983 murder ID'd
Halts AI model launch in EU
CNN finalizes debate rules
Any time
Past hour
Past 24 hours
Past 7 days
Past 30 days
Best match
Most recent
FDA expands approval for GSK’s RSV vaccine to cover younger at-risk adults
New: The FDA has expanded the approval for GSK’s vaccine to protect against respiratory syncytial virus, or RSV, authorizing its use for at-risk adults as young as 50.
FDA Expands Use of RSV Vaccine to Include More Adults
The FDA expanded the approval of GSK's respiratory syncytial virus (RSV) vaccine (Arexvy) to include adults ages 50 to 59 at risk of RSV-related lower respiratory tract disease (LRTD) due to underlying conditions, the company announced on Friday.
FDA approves RSV vaccine for adults 50 to 59
The Arexvy respiratory syncytial virus (RSV) vaccine, which is already approved for adults 60 and up, is now indicated for use in people ages 50 to 59 years old thanks to recent Food and Drug Administration approval.
US FDA approves Moderna's RSV vaccine with lower-than-expected efficacy in its label
The U.S. Food and Drug Administration approved Moderna's respiratory syncytial virus (RSV) vaccine, the company announced on Friday, giving it a shot at much-needed new revenue from a second product.
FDA Gives Nod to RSV Vaccine for People in Their 50s
For the first time, an RSV vaccine has been approved for use in adults in their fifties. GSK's Arexy appears to have similar safety for folks ages 50-59 as that see
Adults 60+ Will Have 3 RSV Vaccines to Choose From This Year
Moderna's RSV vaccine, the first RSV vaccine to use mRNA, earned FDA approval for adults 60 and up. Here's what you need to know.
FDA Approves Moderna’s RSV Vaccine For Older Adults
CIDRAP reports on the approval of Moderna's mRNA vaccine, called mRESVIA, which is expected to be available during the 2024-25 respiratory virus season. Other news is on a rise in whooping cough cases and the latest developments on the bird flu virus.
FDA approves Moderna's RSV vaccine, its second marketed product
The Food and Drug Administration approved Moderna's RSV vaccine to prevent lower respiratory tract disease in adults aged 60 or older
FDA Approves New RSV Vaccine for Individuals Aged 50-59
On Friday, the Food and Drug Administration (FDA) approved Arexvy, a vaccine designed to prevent lower respiratory tract disease (LRTD) caused by respiratory syncytial virus (RSV), for
GSK's RSV Vaccine Arexvy Gets FDA Nod for Adults 50-59 Years
GSK GSK announced that the FDA has approved the expanded use of its respiratory syncytial virus (RSV) vaccine, Arexvy for adults aged 50-59 who are at increased risk of RSV disease. Arexvy is currently approved in the United States,
Des Moines Register
15d
FDA approves Moderna's RSV vaccine, its second marketed product
The U.S. Food and
Drug
Administration has approved Moderna's
respiratory syncytial virus
vaccine
, the company announced on Friday, giving it a shot at much-needed new revenue from a second ...
The American Journal of Managed Care
5d
FDA Approves Expanded Age Indication for RSV Vaccine Arexvy
The first
respiratory syncytial virus
(
RSV
)
vaccine
has been approved for adults aged 50 to 59 years who are at ...
Results that may be inaccessible to you are currently showing.
Hide inaccessible results
Feedback